728 related articles for article (PubMed ID: 26993976)
1. Assessment of Device-Related Thrombus and Associated Clinical Outcomes With the WATCHMAN Left Atrial Appendage Closure Device for Embolic Protection in Patients With Atrial Fibrillation (from the PROTECT-AF Trial).
Main ML; Fan D; Reddy VY; Holmes DR; Gordon NT; Coggins TR; House JA; Liao L; Rabineau D; Latus GG; Huber KC; Sievert H; Wright RF; Doshi SK; Douglas PS
Am J Cardiol; 2016 Apr; 117(7):1127-34. PubMed ID: 26993976
[TBL] [Abstract][Full Text] [Related]
2. Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes.
Dukkipati SR; Kar S; Holmes DR; Doshi SK; Swarup V; Gibson DN; Maini B; Gordon NT; Main ML; Reddy VY
Circulation; 2018 Aug; 138(9):874-885. PubMed ID: 29752398
[TBL] [Abstract][Full Text] [Related]
3. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
[TBL] [Abstract][Full Text] [Related]
4. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Reddy VY; Doshi SK; Sievert H; Buchbinder M; Neuzil P; Huber K; Halperin JL; Holmes D;
Circulation; 2013 Feb; 127(6):720-9. PubMed ID: 23325525
[TBL] [Abstract][Full Text] [Related]
5. Transesophageal echocardiographic diagnosis of a WATCHMAN left atrial appendage closure device thrombus 10 years following implantation.
Shamim S; Magalski A; Chhatriwalla AK; Allen KB; Huber KC; Main ML
Echocardiography; 2017 Jan; 34(1):128-130. PubMed ID: 27862233
[TBL] [Abstract][Full Text] [Related]
6. Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients.
Kubo S; Mizutani Y; Meemook K; Nakajima Y; Hussaini A; Kar S
JACC Clin Electrophysiol; 2017 Dec; 3(12):1380-1386. PubMed ID: 29759668
[TBL] [Abstract][Full Text] [Related]
7. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.
Reddy VY; Holmes D; Doshi SK; Neuzil P; Kar S
Circulation; 2011 Feb; 123(4):417-24. PubMed ID: 21242484
[TBL] [Abstract][Full Text] [Related]
8. Real-world survival data of device-related thrombus following left atrial appendage closure: 4-year experience from a single center.
Bai Y; Xue X; Duenninger E; Muenzel M; Jiang L; Keil T; Fazakas A; Yu J
Heart Vessels; 2019 Aug; 34(8):1360-1369. PubMed ID: 30820642
[TBL] [Abstract][Full Text] [Related]
9. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit.
Gangireddy SR; Halperin JL; Fuster V; Reddy VY
Eur Heart J; 2012 Nov; 33(21):2700-8. PubMed ID: 23008509
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
Holmes DR; Kar S; Price MJ; Whisenant B; Sievert H; Doshi SK; Huber K; Reddy VY
J Am Coll Cardiol; 2014 Jul; 64(1):1-12. PubMed ID: 24998121
[TBL] [Abstract][Full Text] [Related]
12. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation.
Alli O; Doshi S; Kar S; Reddy V; Sievert H; Mullin C; Swarup V; Whisenant B; Holmes D
J Am Coll Cardiol; 2013 Apr; 61(17):1790-8. PubMed ID: 23500276
[TBL] [Abstract][Full Text] [Related]
13. Impact of Peridevice Leak on 5-Year Outcomes After Left Atrial Appendage Closure.
Dukkipati SR; Holmes DR; Doshi SK; Kar S; Singh SM; Gibson D; Price MJ; Natale A; Mansour M; Sievert H; Houle VM; Allocco DJ; Reddy VY
J Am Coll Cardiol; 2022 Aug; 80(5):469-483. PubMed ID: 35902169
[TBL] [Abstract][Full Text] [Related]
14. Predictors of thrombus formation after percutaneous left atrial appendage closure using the WATCHMAN device.
Kaneko H; Neuss M; Weissenborn J; Butter C
Heart Vessels; 2017 Sep; 32(9):1137-1143. PubMed ID: 28477098
[TBL] [Abstract][Full Text] [Related]
15. Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies.
Brouwer TF; Whang W; Kuroki K; Halperin JL; Reddy VY
J Am Heart Assoc; 2019 Dec; 8(23):e013525. PubMed ID: 31752643
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries.
Holmes DR; Reddy VY; Gordon NT; Delurgio D; Doshi SK; Desai AJ; Stone JE; Kar S
J Am Coll Cardiol; 2019 Dec; 74(23):2878-2889. PubMed ID: 31806131
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.
Freeman JV; Hutton DW; Barnes GD; Zhu RP; Owens DK; Garber AM; Go AS; Hlatky MA; Heidenreich PA; Wang PJ; Al-Ahmad A; Turakhia MP
Circ Arrhythm Electrophysiol; 2016 Jun; 9(6):. PubMed ID: 27307517
[TBL] [Abstract][Full Text] [Related]
18. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).
Reddy VY; Möbius-Winkler S; Miller MA; Neuzil P; Schuler G; Wiebe J; Sick P; Sievert H
J Am Coll Cardiol; 2013 Jun; 61(25):2551-6. PubMed ID: 23583249
[TBL] [Abstract][Full Text] [Related]
19. Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy.
Waksman R; Pendyala LK
Am J Cardiol; 2015 Feb; 115(3):378-84. PubMed ID: 25579887
[TBL] [Abstract][Full Text] [Related]
20. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience.
Chun KR; Bordignon S; Urban V; Perrotta L; Dugo D; Fürnkranz A; Nowak B; Schmidt B
Heart Rhythm; 2013 Dec; 10(12):1792-9. PubMed ID: 23973952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
